Top biotech picks combining analyst conviction and fair value upside

Investing.com reports that some biotech stocks are popular with analysts due to strong price targets, while others have modest analyst suggestions but trade below their intrinsic value. Legend Biotech stands out as a balanced choice, with 15 analysts covering it, a 137% upside to their target, and 34.2% fair value upside. Viking Therapeutics commands the most analyst attention with 19 analysts and 186.2% target upside to $92.39, although it trades slightly above fair value at -3.3%.

Legend Biotech's revenue has grown from $69M in 2021 to $1.27B in 2025, while Ardelyx has scaled from $10M to $451M during the same period. Wave Life Sciences has a strong cash balance of $368M against $44M debt, and Sagimet Biosciences has $166M cash with minimal debt. Viking Therapeutics offers the most analyst conviction, but at a premium price, while Legend Biotech provides the most balanced profile of strong analyst support, positive fair value, and revenue growth.